INSM · NASDAQ · Healthcare · $24.7B· Nat'l Pension stake 0.01% (2026-06-30)· Short % 6.9%
$112.58+0.9%vs prev closeclose of 2026-10-30 · not real-time
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is…· Source: company profile (yfinance/Yahoo Finance)
⚠ Value-trap warning
This stock is flagged by our value-trap filter (e.g. shrinking earnings, negative free cash flow, or losses). Cheap can stay cheap — read why before acting.
Which value-trap type
vs. analyst consensus target. The target is an opinion, not a prediction or buy signal.
Some axes lack data (–)
A summary of valuation factors — not a buy recommendation. You decide.
| Company | PER | PBR | ROE | Div | Score |
|---|---|---|---|---|---|
| Insmed Incorporated | – | 34.0 | -72% | 0.0% | 32 |
| Incyte Corp. | 15.3 | 4.3 | 8% | 0.0% | 38 |
| United Therapeutics Corporation | 21.4 | 4.0 | 19% | 0.0% | 55 |
| Koninklijke Philips N.V. NY Registry Shares | 20.1 | 2.0 | 10% | 3.7% | 49 |
| STERIS plc (Ireland) | 27.8 | 3.1 | 11% | 1.2% | 46 |
| Alnylam Pharmaceuticals Inc. | 27.8 | 6.1 | 140% | 0.0% | 59 |
Same sector, nearest by market cap · – = no data (value traps excluded)
Held by notable investors (13F)
Chart patterns matched (observational)
Technical patterns for reference — not a buy recommendation.
Open-market buys & sells by this company's officers & directors (SEC Form 4)
Observational — buy/sell facts only, not a recommendation. Filing dates (the trade was 1–2 business days earlier). Routine comp (option exercises, grants) excluded — discretionary buys/sells only.
The chart (long-term trend, Ichimoku cloud) is for observation only — not a buy or sell signal.
Shows only where the current price sits within the channel structure (based on past swings).
The channel, levels and gaps are observational geometry showing where the current price sits within past swing structure. They are not a rebound/bottom probability, a price target, or a buy/sell signal — plain chart patterns carry no reliable predictive edge (our backtest conclusion).
A highlight of the key metrics detailed below.
Top-tier in 0 of 4 evaluated strategies
Ranks within the US market — tap to open that ranking (ranks are per market).
Past returns — they do not guarantee future results.
EV as reported by our data provider (Yahoo Finance) · net debt is our own calc (total debt − cash) · definitions differ, so EV need not equal market cap + net debt (minority interest, preferred stock)
Color: green = healthy, red = caution (absolute thresholds, value/quality metrics only). Downside vol & Sortino are annualized. Max drawdown = largest drop from a 3-year peak; volatility = 1-year annualized. Price/Graham < 1 = below Graham fair value (profitable, positive-equity names only). RSI < 30 = oversold. For reference only.
A Japanese trend tool. Price above the 'cloud' is supportive; below is weak. A strong uptrend doesn't mean it's cheap — stocks that have run up are usually more expensive.